Obesity Clinical Trial
Official title:
Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects
Verified date | November 2023 |
Source | Perrigo CSCI |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main study objective is to evaluate the efficacy of IQP-AE-103 in reducing body weight in overweight and moderately obese subjects, in the context of an energy restricted diet. Further objectives are to evaluate the beneficial potential of IQP-AE-103 on waist circumference, blood pressure and blood glucose and lipid levels, quality of life, as well as its safety and tolerability
Status | Completed |
Enrollment | 178 |
Est. completion date | April 8, 2021 |
Est. primary completion date | April 8, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Men and women from 18 to 70 years old 2. Body mass index (BMI) 25 kg/m2 - 34.9 kg/m2 3. Having at least one of the following traits: - waist circumference = 94 cm in men and = 80 cm in women - triglyceride levels = 150 mg/dL (1.7 mmol/L) - high-density lipoprotein cholesterol (HDL-C) levels: = 40 mg/dL (1.0 mmol/L) in men and = 50 mg/dL (1.3 mmol/L) in women - blood pressure (BP), average value of the last two values of the triplicate measurement: systolic BP = 130 mmHg, diastolic BP = 85 mmHg - fasting blood glucose = 100 mg/dL 4. Desire to lose weight 5. Readiness and ability to complete the study, according to investigator's judgement following the screening interview 6. Accustomed to regular daily consumption of 3 main meals (breakfast, lunch, dinner) 7. Consistent and stable body weight in the last 3 months prior to V1 (less than 5% self-reported change) 8. Subject's agreement to comply with study procedures, in particular: - to adhere to diet recommendation during the study - to take IP as recommended - to avoid the use of other weight loss and/or management products and/or programs during the study - to keep the habitual level of physical activity - to complete the subject diary and study questionnaires 9. Women of childbearing potential: - commitment to use contraception methods - negative pregnancy testing (beta human chorionic gonadotropin test in urine) at V1 10. Readiness not to participate in another clinical study during this study Participation is based upon written informed consent by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study. Exclusion Criteria: 1. Known allergy or hypersensitivity to the components of the investigational product or source plants 2. Pathological electrocardiogram (ECG) at V1 3. History and/or presence of clinically significant condition/ disorder, which per investigator's judgement could interfere with the results of the study or the safety of the subject, e.g.: - untreated or unstable thyroid gland disorder - hypertension (regular systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg) - acute or chronic gastrointestinal (GI) disease or digestion/ absorption disorders (e.g. inflammatory bowel disease, coeliac disease, pancreatitis etc.) - diabetes mellitus - any other relevant serious organ or systemic diseases 4. Significant surgery within the last 6 months prior to V1 or planned within the study period: - GI surgery - liposuction 5. History of eating disorders like bulimia, anorexia nervosa, binge-eating within the last 12 months prior to V1 6. Deviation of safety laboratory parameter(s) at V1 (excluding those stated in the inclusion criteria) that is: - clinically significant or - >2x upper limit of normal, unless the deviation is justified by a previously known not clinically relevant condition (e.g. Gilbert's syndrome) 7. Any electronic medical implant 8. Regular medication and/or supplementation and/or treatment within the last 3 months prior to V1 and during the study: - that could influence body weight (e.g. systemic corticosteroids) - that could influence gastrointestinal functions (e.g. laxatives, opioids, anticholinergics etc.) as per investigator judgement - for weight management (e.g. fat binder, carbohydrate/ starch blocker, fat burner, satiety products, acupuncture etc.) - that could influence lipid levels, blood pressure and/or glycemic control 9. Self-reported smoking cessation within 6 months prior to V1 and/or during the study (regular smoking during the study at the same level as prior to the study is allowed) 10. Women of child-bearing potential: pregnancy or nursing 11. History of or current abuse of drugs, alcohol or medication 12. Participation in another study during the last 30 days prior to V1 13. Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures |
Country | Name | City | State |
---|---|---|---|
Germany | analyze & realize GmbH | Berlin |
Lead Sponsor | Collaborator |
---|---|
Perrigo CSCI | Analyze & Realize |
Germany,
Uebelhack R, Bongartz U, Seibt S, Bothe G, Chong PW, De Costa P, Wszelaki N. Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects. J Obes. 2019 Feb 3;2019:3412952. doi: 10.1155/2019/3412952. eCollection 2019. Erratum In: J Obes. 2019 Jul 11;2019:6189724. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Difference in change in waist circumference after 24 weeks weeks of IP intake, in comparison to baseline | weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in body weight (%) change after 24 weeks of IP intake, in comparison to baseline | Difference in body weight (%) change after 24 weeks | 24 weeks | |
Other | Difference in body weight (kg) change after 16 weeks of IP intake, in comparison to baseline | Difference in body weight (kg) change after 16 weeks | 16 weeks | |
Other | Difference in body weight (%) change after 16 weeks of IP intake, in comparison to baseline | Difference in body weight (%) change after 16 weeks | 16 weeks | |
Other | Difference in BMI change after 16 weeks of IP intake, in comparison to baseline | Difference in BMI change after 16 weeks of IP intake, | 16 weeks | |
Other | Difference in body fat mass (kg) change assessed per BIA after 24 weeks of IP intake, in comparison to baseline | Difference in body fat mass (kg) change assessed per BIA after 24 weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in change in quality of life parameters assessed per IWQOL-LITE after 24 weeks of IP intake, in comparison to baseline | Difference in change in quality of life parameters assessed per IWQOL-LITE after 24 weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in body fat mass (kg) change assessed per BIA after 16 weeks of IP intake, in comparison to baseline | Difference in body fat mass (kg) change assessed per BIA after 16 weeks of IP intake, in comparison to baseline | 16 weeks | |
Other | Difference in change in quality of life parameters assessed per IWQOL-LITE after 16 weeks of IP intake, in comparison to baseline | Difference in change in quality of life parameters assessed per IWQOL-LITE after 16 weeks of IP intake, in comparison to baseline | 16 weeks | |
Other | Difference in change in systolic blood pressure after 24 weeks of IP intake, in comparison to baseline | Difference in change in systolic blood pressure after 24 weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in change in diastolic blood pressure after 24 weeks of IP intake, in comparison to baseline | Difference in change in diastolic blood pressure after 24 weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in global evaluation of efficacy by subject and investigator at study end | Difference in global evaluation of efficacy by subject and investigator at study end | 24 weeks | |
Other | Difference in evaluation of success with respect to the original goal/motivation of the subject to participate at study end | Difference in evaluation of success with respect to the original goal/motivation of the subject to participate at study end | 24 weeks | |
Other | Difference in change in waist circumference after 16 weeks of IP intake, in comparison to baseline | Difference in change in waist circumference after 16 weeks of IP intake, in comparison to baseline | 16 weeks | |
Other | Difference in change in systolic blood pressure after 16 weeks of IP intake, in comparison to baseline | Difference in change in systolic blood pressure after 16 weeks of IP intake, in comparison to baseline | 16 weeks | |
Other | Difference in change in diastolic blood pressure after 16 weeks of IP intake, in comparison to baseline | Difference in change in diastolic blood pressure after 16 weeks of IP intake, in comparison to baseline | 16 weeks | |
Other | Difference in change in TG after 24 weeks of IP intake, in comparison to baseline | Difference in change in TG after 24 weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in change in HDL-C after 24 weeks of IP intake, in comparison to baseline | Difference in change in HDL-C after 24 weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in change in LDL-C after 24 weeks of IP intake, in comparison to baseline | Difference in change in LDL-C after 24 weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in change in TC after 24 weeks of IP intake, in comparison to baseline | Difference in change in TC after 24 weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in change in fasting blood glucose after 24 weeks of IP intake, in comparison to baseline | Difference in change in fasting blood glucose after 24 weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in body weight (kg) change after 8 weeks of IP intake, in comparison to baseline | Difference in body weight (kg) change after 8 weeks of IP intake, in comparison to baseline | 8 weeks | |
Other | Difference in body weight (%) change after 8 weeks of IP intake, in comparison to baseline | Difference in body weight (%) change after 8 weeks of IP intake, in comparison to baseline | 8 weeks | |
Other | Difference in BMI change after 8 weeks of IP intake, in comparison to baseline | Difference in BMI change after 8 weeks of IP intake, in comparison to baseline | 8 weeks | |
Other | Difference in body fat mass (kg) change assessed per BIA after 8 weeks of IP intake, in comparison to baseline | Difference in body fat mass (kg) change assessed per BIA after 8 weeks of IP intake, in comparison to baseline | 8 weeks | |
Other | Difference in change in quality of life parameters assessed per IWQOL-LITE after 8 weeks of IP intake, in comparison to baseline | Difference in change in quality of life parameters assessed per IWQOL-LITE after 8 weeks of IP intake, in comparison to baseline | 24 weeks | |
Other | Difference in change in waist circumference after 8 weeks of IP intake, in comparison to baseline | Difference in change in waist circumference after 8 weeks of IP intake, in comparison to baseline | 8 weeks | |
Other | Difference in body weight (kg) change after 4 weeks of IP intake, in comparison to baseline | Difference in body weight (kg) change after 4 weeks of IP intake, in comparison to baseline | 4 weeks | |
Other | Difference in body weight (%) change after 4 weeks of IP intake, in comparison to baseline | Difference in body weight (%) change after 4 weeks of IP intake, in comparison to baseline | 4 weeks | |
Other | Difference in BMI change after 4 weeks of IP intake, in comparison to baseline | Difference in BMI change after 4 weeks of IP intake, in comparison to baseline | 4 weeks | |
Other | Difference in change in systolic blood pressure after 8 weeks of IP intake, in comparison to baseline | Difference in change in systolic blood pressure after 8 weeks of IP intake, in comparison to baseline | 8 weeks | |
Other | Difference in change in diastolic blood pressure after 8 weeks of IP intake, in comparison to baseline | Difference in change in diastolic blood pressure after 8 weeks of IP intake, in comparison to baseline | 8 weeks | |
Other | Difference in change in TG after 16 weeks of IP intake, in comparison to baseline | Difference in change in TG after 16 weeks of IP intake, in comparison to baseline | 16 weeks | |
Other | Difference in change in HDL-C after 16 weeks of IP intake, in comparison to baseline | Difference in change in HDL-C after 16 weeks of IP intake, in comparison to baseline | 16 weeks | |
Other | Difference in change in LDL-C after 16 weeks of IP intake, in comparison to baseline | Difference in change in LDL-C after 16 weeks of IP intake, in comparison to baseline | 16 weeks | |
Other | Difference in change in TC after 16 weeks of IP intake, in comparison to baseline | Difference in change in TC after 16 weeks of IP intake, in comparison to baseline | 16 weeks | |
Other | Difference in change in fasting blood glucose after 16 weeks of IP intake, in comparison to baseline | Difference in change in fasting blood glucose after 16 weeks of IP intake, in comparison to baseline | 16 weeks | |
Other | Difference in body fat mass (kg) change assessed per BIA after 4 weeks of IP intake, in comparison to baseline | Difference in body fat mass (kg) change assessed per BIA after 4 weeks of IP intake, in comparison to baseline | 4 weeks | |
Primary | Difference in body weight | Difference in body weight (kg) change after 24 weeks of IP intake, in comparison to baseline | 24 weeks | |
Secondary | Difference in BMI | Difference in BMI change after 24 weeks of IP intake, in comparison to baseline | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |